Second- and third-generation drug-eluting coronary stents: Progress and safety

Herz

Volumn 36, Issue 3, 2011, Pages 190-197

  Akin, I ^a   Schneider, H ^a   Ince, H ^a   Kische, S ^a   Rehders, T C ^a   Chatterjee, T ^a   Nienaber, C A ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Bioabsorbable; Drug eluting stent; Everolimus; Stent thrombosis; Zotarolimus

Indexed keywords

ANTIMITOTIC AGENT; EVEROLIMUS; MAGNESIUM; PACLITAXEL; POLYLACTIDE; POLYMER; RAPAMYCIN; TISSUE SCAFFOLD; UMIROLIMUS; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; APOPTOSIS; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; CLINICAL EFFECTIVENESS; CORONARY ARTERY ANEURYSM; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; HYPEREOSINOPHILIA; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MATERIAL COATING; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOGENICITY; VASCULITIS;

EID: 85027934870     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-011-3458-z     Document Type: Review

References (47)

1. Stone GW, Moses JW, Ellis SG et al (2007) Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008 (Pubitemid 46376800)
2. Stettler C, Wandel S, Allemann S et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937-948 (Pubitemid 47393576)
3. Nienaber CA, Akin I, Schneider S et al (2009) Clinical outcomes after sirolimus-eluting, paclitaxel-eluting and bare-metal stents (from the first phase of the prospective multicenter German DES.DE registry. Am J Cardiol 104:1362-1369
4. Pfisterer M, Brunner-La Rocca HP, Buser PT et al (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584-2591 (Pubitemid 44881238)
5. Lagerqvist B, James SK, Stenestrand U et al (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009-1019 (Pubitemid 46376801)
6. Kirtane AJ, Gupta A, Iyengar S et al (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119:3198-3206
7. Mauri L, Hsieh WH, Massaro JM et al (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020-1029 (Pubitemid 46376802)
8. Finn AV, Kolodgie FD, Harnek J et al (2005) Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112:270-278 (Pubitemid 40982311)
9. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701-705
10. Iakovou I, Schmidt T, Bonizzoni E et al (2005) ncidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126-2130 (Pubitemid 40617065)
11. Daemen J, Wenaweser P, Tsuchida K et al (2007) Early and late coronary stent thrombosis of sirolimus- eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667-678 (Pubitemid 46281313)
12. Wenaweser P, Daemen J, Zwahlen M et al (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52:1134-1140
13. Garg P, Cohen DJ, Gaziano T, Mauri L (2008) Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol 51:1844-1853 (Pubitemid 351615257)
14. Stone GW, Ellis SG, Colombo A et al (2007) Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115:2842-2847 (Pubitemid 46869671)
15. Virmani R, Liistro F, STankovic G et al (2002) Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106:2649-2651 (Pubitemid 35364917)
16. Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202 (Pubitemid 43929240)
17. Kastrati A, Mehilli J, Dirschinger J et al (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103:2816-2821 (Pubitemid 32550070)
18. Popma JJ, Mauri L, O'Shaughnessy C et al (2009) Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Interv 2:133-139
19. Meredith IT, Ormiston J, Whitbourn R et al (2005) First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 1:157-164
20. Awata M, Nanto S, Uematsu M et al (2008) Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. J Am Coll Cardiol 52:789-790
21. Guagliumi G, Sirbu V, Musumeci G et al (2010) Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting STent Investigation (OCTDESI). Circ Cardiovasc Interv 3:367-375
22. Fajadet J, Wijns W, Laarman GJ et al (2006) domized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114:798-806 (Pubitemid 44268230)
23. Kandzari DE, Leon MB, Popma JJ et al (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J AM Coll Cardiol 48:2440-2447 (Pubitemid 44881222)
24. Leon MB, Mauri L, Popma JJ et al (2010) A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 55:543-554
25. Rasmussen K, Maeng M, Kaltoft A et al (2010) Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT-OUT III): a randomised controlled superiority trial. Lancet 375:1090-1099
26. Lotan C, Meredith IT, Liu M et al (2009) Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry. J Am Coll Cardiol Interv 2:1227-1235
27. Camenzind E, Wijns W, Mauri L et al (2009) Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J 158:902-909
28. Serruys PW, Ong AT, Piek JJ et al (2005) A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 1:58-65
29. Joner M, Nakazawa G, Finn AV et al (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333-342 (Pubitemid 352001347)
30. Wiemer M, Serruys PW, Miquel-Hebert K et al (2010) Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv 75:997-1003
31. Garg S, Serruys PW, Onuma Y et al (2009) 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary STent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2:1190-1198
32. Stone GW, Midei M, Newman W et al (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299:1903-1913 (Pubitemid 351574920)
33. Kedhi E, Joesoef KS, McFadden E et al (2010) Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375:201-209
34. Nienaber CA (2010) Everolimus or paclitaxel-eluting stent: go COMPARE. Lancet 375:174-176
35. Claessen BE, Beijk MA, Legrand V et al (2009) Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv 2:339-347
36. Stone GW, Rizvi A, Newman W et al (2010) Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362:1663-1674
37. Lansky AJ, Applegate R, Hermiller JB et al (2009) Side-branch occlusion with Xience V everolimus-eluting and Taxus Express2 paclitaxel-eluting stents: two-year results from the SPIRIT III randomized trial. Am J Cardiol 104(Suppl 6A):135D
38. Torre Hernández JM de la, Alfonso F, Gimeno F et al (2010) Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol SObre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv 3:911-919
39. Serruys PW, Silber S, Garg S et al (2010) Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 363:136-146
40. Meredith IT, Worthley S, Whitbourn R et al (2007) The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 3:50-53
41. Windecker S, Serruys PW, Wandel S et al (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372:1163-1173
42. Barlis P, Regar E, Serruys PW et al (2010) An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 31:165-176
43. Mehilli J, Kastrati A, Wessely R et al (2006) Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113:273-279
44. Ruef J, Störger H, Schwarz F, Haase J (2008) Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv 71:333-339 (Pubitemid 351428151)
45. Ormiston JA, Serruys PW, Regar E et al (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899-907 (Pubitemid 351384734)
46. Onuma Y, Serruys PW, Ormiston JA et al (2010) Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 6:447-453
47. Erbel R, Di Mario C, Bartunek J et al (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369:1869-1875 (Pubitemid 46829357)